Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Olympus: Strong Overseas Sales of Medical Endoscopes Support Growth
June 10, 2002
- Tanabe: Sales Decline Due to Transfer of Diagnostics to Eiken
June 10, 2002
- Toho Pharm: Profits Down Despite 16.8% Increase in Sales
June 10, 2002
- Cost Calculation Method Employed for Elastase, Acetylcysteine
June 10, 2002
- Ono: Opalmon, Onon Drive Sales, Profits
June 10, 2002
- Vital-Net: Becomes No. 1 Drug Wholesaler in Tohoku Region
June 10, 2002
- OTC NEWS IN BRIEF
June 10, 2002
- Tsumura: Net Profits for 1st Time in 5 Years
June 10, 2002
- BULLETIN
June 10, 2002
- REGULATORY NEWS IN BRIEF
June 10, 2002
- Kaken: Sales Up 4.2%, Effects of Competitors on Artz Are Minimal
June 10, 2002
- Taisho Licenses mGluR Agonists to Merck
June 10, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 10, 2002
- SSP: Sales, Profits Plummet Due to Slump in Self-medication
June 10, 2002
- Chugai, Biostar, Jicchuken Create Post-genomic Research Company in Singapore
June 10, 2002
- Late PII Results on Humanized Antibody MRA Reported: Chugai
June 10, 2002
- Mochida: Sales Down Due to Decline in Mainstays
June 10, 2002
- Sosei Introduces Brain Tumor Treatment from KS Biomedix of the UK
June 10, 2002
- Fulminant Type 1 Diabetes Can Be Fatal if not Treated Immediately
June 10, 2002
- Kyorin: New Record-high Consolidated Sales Reported
June 10, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…